Catalent, Inc. (CTLT): Price and Financial Metrics


Catalent, Inc. (CTLT)

Today's Latest Price: $114.73 USD

2.09 (-1.79%)

Updated Jan 25 2:41pm

Add CTLT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CTLT Stock Summary

  • CTLT has a higher market value than 88.92% of US stocks; more precisely, its current market capitalization is $19,239,973,398.
  • CTLT's current price/earnings ratio is 77.21, which is higher than 87.09% of US stocks with positive earnings.
  • The price/operating cash flow metric for Catalent Inc is higher than 85.72% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to CTLT, based on their financial statements, market capitalization, and price volatility, are AME, LDOS, DGX, TSN, and BR.
  • Visit CTLT's SEC page to see the company's official filings. To visit the company's web site, go to www.catalent.com.

CTLT Stock Price Chart Interactive Chart >

Price chart for CTLT

CTLT Price/Volume Stats

Current price $114.73 52-week high $120.48
Prev. close $116.82 52-week low $31.04
Day low $114.25 Volume 498,863
Day high $117.89 Avg. volume 977,953
50-day MA $104.04 Dividend yield N/A
200-day MA $86.43 Market Cap 18.90B

Catalent, Inc. (CTLT) Company Bio


Catalent provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The company was founded in 2007 and is founded in Somerset, New Jersey.

CTLT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$114.73$0.8 -99%

Below please find a table outlining a discounted cash flow forecast for CTLT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Catalent Inc ranked in the 4th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Catalent Inc, consider:

  • The company's compound free cash flow growth rate over the past 5.18 years comes in at -0.06%; that's greater than merely 17.65% of US stocks we're applying DCF forecasting to.
  • The weighted average cost of capital for the company is 9. This value is greater than merely 23.83% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-99%
1%-99%
2%-99%
3%-99%
4%-99%
5%-99%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CTLT, try STAA, AGHC, ALC, AMRN, and ATRS.


CTLT Latest News Stream


Event/Time News Detail
Loading, please wait...

CTLT Latest Social Stream


Loading social stream, please wait...

View Full CTLT Social Stream

Latest CTLT News From Around the Web

Below are the latest news stories about Catalent Inc that investors may wish to consider to help them evaluate CTLT as an investment opportunity.

Catalent (CTLT) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

The following slide deck was published by Catalent, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 21, 2021

Biotherapeutics Cell Line Development Market with Pandemic Analysis, Growth Rate, New Trend Analysis Forecast To 2027 | Becton Dickinson and Company, Beckman Coulter, Boehringer Ingelheim Group, Catalent

Biotherapeutic drug products encompass various active substances. These substances are either produced or extracted from biological sources. These biotherapeutic drug therapy products are obtained from various recombinant DNA technologies such as interleukins, interferons, etc. There are various advantages of these

OpenPR | January 20, 2021

Catalent, Inc. Announces Second Quarter Fiscal Year 2021 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2021 ended December 31, 2020, before the market open on Tuesday, February 2, 2021. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Yahoo | January 20, 2021

Ayala Pharmaceuticals (AYLA) Soars: Stock Adds 13.2% in Session

Ayala Pharmaceuticals (AYLA) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.

Yahoo | January 20, 2021

Clinical Trial Supply and logistics Market Reach at High CAGR with Technology Innovative, and advanced of applications Major key Companies: DHL, Movianto, Catalent, Patheon, Marken, FedEx, Almac Group

Clinical trials are research studies performed in a group of people called sample that are aimed at evaluating a medical, surgical, or behavioral intervention. It is a primary way for researchers to measure safety, efficacy, side effects and positive effects

OpenPR | January 18, 2021

Read More 'CTLT' Stories Here

CTLT Price Returns

1-mo N/A
3-mo 25.40%
6-mo 40.74%
1-year 86.31%
3-year 142.25%
5-year 399.70%
YTD 10.24%
2020 84.85%
2019 80.56%
2018 -24.10%
2017 52.37%
2016 7.71%

Continue Researching CTLT

Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:

Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0513 seconds.